GlassScriptPhysician profile
Jerry A Cohen
NPI 1629015680
$1,843.50
in general payments reported to CMS, 2019-2025
32 companies · $342 in 2025
The $342 reported for 2025 was more than what 75% of Geriatric Medicine (Family Medicine) providers received nationally (typical 2025 total: $119).
See the full distribution for Geriatric Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $334 · 2020: $258 · 2021: $285 · 2022: $248 · 2023: $216 · 2024: $162 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $720.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $719.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $235.22 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $140.00 | 2023-2025 | Rexulti, Nuedexta |
| Astellas Pharma US INC | $138.85 | 2020-2023 | Myrbetriq |
| Sun Pharmaceutical Industries INC. | $132.33 | 2020-2022 | |
| Amarin Pharma, INC. | $129.10 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $96.58 | 2019-2025 | Nuplazid |
| Novartis Pharmaceuticals Corporation | $90.92 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $88.06 | 2019-2024 | Invega Sustenna |
| Sunovion Pharmaceuticals INC. | $76.42 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $75.30 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $74.52 | 2025 | |
| Lilly USA, LLC | $54.87 | 2022-2025 | Kisunla, Amyvid |
| Nestle Healthcare Nutrition INC. | $53.41 | 2021-2022 | |
| Lundbeck LLC | $50.01 | 2023-2025 | Rexulti |
| Sk Life Science, INC. | $37.45 | 2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $36.86 | 2022-2025 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.65 | 2022-2023 | |
| Ucb, INC. | $36.20 | 2023 | Nayzilam, Briviact |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.41 | 2022-2025 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $26.12 | 2022 | |
| Argenx US, INC. | $24.53 | 2025 | Vyvgart Hytrulo |
| Biogen, INC. | $21.65 | 2023 | Vumerity, Avonex |
| E.R. Squibb & Sons, L.L.C. | $19.55 | 2025 | Cobenfy |
| Urovant Sciences INC | $19.48 | 2021 | |
| Merck Sharp & Dohme LLC | $16.77 | 2024 | Dificid |
| Vivus LLC | $16.65 | 2019 | |
| Amgen INC. | $16.18 | 2025 | Repatha |
| Eisai INC. | $15.36 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.33 | 2025 | |
| Vertical Pharmaceuticals, LLC | $15.28 | 2019 | |
| Aprecia Pharmaceuticals, LLC | $12.46 | 2021 | |
| Hikma Pharmaceuticals USA | $10.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.